Type 2 diabetes mellitus
Conditions
Interventions
control group:Short-term intensive insulin therapy
trial group:Short-term intensive intervention with insulin, metformin, and dapagliflozin
Sponsors
The first People's Hospital of Xuzhou
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria are as follows: 1. consecutive diabetic patients who visited our hospital; 2. men and women aged 20 to 70 years; 3. patients with type 2 diabetes mellitus; 4. patients with a duration of type 2 diabetes mellitus of 5?years or less; 5. hemoglobin A1c = 1.1 µg/L; 7. body mass index >= 25 kg/m2; 8. women who had to be non-child bearing or willing to use birth control; 9. participant willing to perform regular capillary blood glucose monitoring; 10. able and willing to inject insulin; 11. able and willing to provide informed consent.
Exclusion criteria
Exclusion criteria: The exclusion criteria are as follows: 1. current use of insulin; 2. history of hypoglycemia unawareness; history of severe hypoglycemia requiring assistance within the last 5 years; 3. renal dysfunction as evidenced by estimation of the glomerular filtration rate = 2.5 times upper limit of normal at the time of enrollment; 6. history of pancreatitis; 7. cardiovascular disease including any of: systolic blood pressure >= 180 mmHg or diastolic blood pressure >= 110 mmHg; peripheral vascular disease; left bundle branch block or second or third degree AV block; tachyarrhythmias or bradyarrhythmias with uncontrolled ventricular rate; stenotic valvular heart disease; cardiomyopathy; history of heart failure; h) history of aortic dissection; documented history of angina or coronary artery disease; history of stroke or transient ischemic attack; 8. history of any disease requiring continuous systemic glucocorticoid treatment; 9. history of any major illness with a life expectancy of 14 alcoholic drinks per week in men and > 7 alcoholic drinks per week in women); and (12) known hypersensitivity to insulin, metformin, or dapagliflozin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting C-peptide;Fasting Plasma Glucose;Glycosylated Hemoglobin;Hepatorenal Function;Blood Fat;Height;Weight;Incidence of diabetes remission; | — |
Countries
China
Contacts
Public ContactHao Hu
The first People's Hospital of Xuzhou
Outcome results
None listed